In conclusion, the therapeutic potential of GLP-1 receptor agonists, insulin analogs, metformin, and PPARγ agonists lies in their ability to target various pathophysiological mechanisms in AD, offering hope for more effective treatments. This evidence concerns the gene GLP1R and Alzheimer disease.